Effects of small interfering RNA-mediated hepatic glucagon receptor inhibition on lipid metabolism in db/db mice

Journal of Lipid Research

Volumn 54, Issue 10, 2013, Pages 2615-2622

  Han, Seongah ^a   Akiyama, Taro E ^a   Previs, Stephen F ^a   Herath, Kithsiri ^a   Roddy, Thomas P ^a   Jensen, Kristian K ^a   Guan, Hong Ping ^a   Murphy, Beth A ^a   McNamara, Lesley A ^a   Shen, Xun ^a   Strapps, Walter ^a   Hubbard, Brian K ^a   Pinto, Shirly ^a   Li, Cai ^a   Li, Jing ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Diabetes mellitus; Dyslipidemia; Glucose

Indexed keywords

CHOLESTEROL; GLUCAGON RECEPTOR; GLUCOSE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; LIPID ANALYSIS; LIPID METABOLISM; LIPOGENESIS; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION;

DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; LIPOGENESIS; LIPOPROTEINS, LDL; LIVER; MALE; MICE; MICE, OBESE; RECEPTORS, GLUCAGON; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRIGLYCERIDES;

EID: 84884148295     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M035592     Document Type: Article

References (29)

1. D'Alessio, D. 2011. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes. Metab. 13 (Suppl.): 126-132.
2. Petersen, K. F., and J. T. Sullivan. 2001. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 44: 2018-2024.
3. Qureshi, S. A., C. M. Rios, D. Xie, X. Yang, L. M. Tota, V. D. Ding, Z. Li, A. Bansal, C. Miller, S. M. Cohen, et al. 2004. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes. 53: 3267-3273.
4. Winzell, M. S., C. L. Brand, N. Wierup, U. G. Sidelmann, F. Sundler, E. Nishimura, and B. Ahren. 2007. Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia. 50: 1453-1462.
5. Sloop, K. W., J. X. Cao, A. M. Siesky, H. Y. Zhang, D. M. Bodenmiller, A. L. Cox, S. J. Jacobs, J. S. Moyers, R. A. Owens, A. D. Showalter, et al. 2004. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J. Clin. Invest. 113: 1571-1581.
6. Liang, Y., M. C. Osborne, B. P. Monia, S. Bhanot, W. A. Gaarde, C. Reed, P. She, T. L. Jetton, and K. T. Demarest. 2004. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 53: 410-417.
7. Sørensen, H., C. L. Brand, S. Neschen, J. J. Holst, K. Fosgerau, E. Nishimura, and G. I. Shulman. 2006. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes. 55: 2843-2848.
8. Gelling, R. W., X. Q. Du, D. S. Dichmann, J. Romer, H. Huang, L. Cui, S. Obici, B. Tang, J. J. Holst, C. Fledelius, et al. 2003. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. USA. 100: 1438-1443.
9. Parker, J. C., K. M. Andrews, M. R. Allen, J. L. Stock, and J. D. McNeish. 2002. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290: 839-843.
10. Conarello, S. L., G. Jiang, J. Mu, Z. Li, J. Woods, E. Zycband, J. Ronan, F. Liu, R. S. Roy, L. Zhu, et al. 2007. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin- mediated beta cell loss and hyperglycaemia. Diabetologia. 50: 142-150.
11. Kelly, R. P., P. Garhyan, E. J. Abu-Raddad, H. Fu, C. Lim, M. J. Prince, J. A. Pinaire, M. Loh, and M. A. Deeg. 2011. Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose (FBG) and HbA1c in patients with type 2 diabetes mellitus (T2DM) [abstract]. Diabetes. 60 (Suppl.) : A84.
12. Engel, S. S., L. Xu, P. J. Andryuk, M. J. Davies, J. Amatruda, K. Kaufman, and B. J. Goldstein. 2011. Efficacy and tolerability of MK- 0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) [abstract]. Diabetes. (Suppl.) : A85.
13. Krauss, R. M. 2004. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 27: 1496-1504.
14. Tadin-Strapps, M., L. B. Peterson, A. M. Cumiskey, R. L. Rosa, V. H. Mendoza, J. Castro-Perez, O. Puig, L. Zhang, W. R. Strapps, S. Yendluri, et al. 2011. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J. Lipid Res. 52: 1084-1097.
15. Chen, Z., S. P. Wang, M. L. Krsmanovic, J. Castro-Perez, K. Gagen, V. Mendoza, R. Rosa, V. Shah, T. He, S. J. Stout, et al. 2012. Small molecule activation of lecithin cholesterol acyltransferase modulates lipoprotein metabolism in mice and hamsters. Metabolism. 61: 470-481.
16. Han, S., C. P. Liang, M. Westerterp, T. Senokuchi, C. L. Welch, Q. Wang, M. Matsumoto, D. Accili, and A. R. Tall. 2009. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J. Clin. Invest. 119: 1029-1041.
17. Han, S., A. M. Flattery, D. McLaren, R. Raubertas, S. H. Lee, V. Mendoza, R. Rosa, N. Geoghagen, J. M. Castro-Perez, T. P. Roddy, et al. 2012. Comparison of lipoprotein separation and lipid analysis methodologies for human and cynomolgus monkey plasma samples. J. Cardiovasc. Transl. Res. 5: 75-83.
18. Jensen, K. K., S. F. Previs, L. Zhu, K. Herath, S. P. Wang, G. Bhat, G. Hu, P. L. Miller, D. G. McLaren, M. K. Shin, et al. 2012. Demonstration of diet-induced decoupling of fatty acid and cholesterol synthesis by combining gene expression array and 2H2O quantification. Am. J. Physiol. Endocrinol. Metab. 30 2: E209 - E217.
19. Lee, W. N., S. Bassilian, H. O. Ajie, D. A. Schoeller, J. Edmond, E. A. Bergner, and L. O. Byerley. 1994. In vivo measurement of fatty acids and cholesterol synthesis using D2O and mass isotopomer analysis. Am. J. Physiol. 266: E699 - E708.
20. Diraison, F., C. Pachiaudi, and M. Beylot. 1996. In vivo measurement of plasma cholesterol and fatty acid synthesis with deuterated water: determination of the average number of deuterium atoms incorporated. Metabolism. 45: 817-821.
21. Mu, J., G. Jiang, E. Brady, Q. Dallas-Yang, F. Liu, J. Woods, E. Zycband, M. Wright, Z. Li, K. Lu, et al. 2011. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia. 54: 2381-2391.
22. Eaton, R. P. 1973. Hypolipemic action of glucagon in experimental endogenous lipemia in the rat. J. Lipid Res. 14: 312-318.
23. Longuet, C., E. M. Sinclair, A. Maida, L. L. Baggio, M. Maziarz, M. J. Charron, and D. J. Drucker. 2008. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 8: 359-371.
24. Xiao, C., M. Pavlic, L. Szeto, B. W. Patterson, and G. F. Lewis. 2011. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes. 60: 383-390.
25. Aubry, F., Y. L. Marcel, and J. Davignon. 1974. Effects of glucagon on plasma lipids in different types of primary hyperlipoproteinemia. Metabolism. 23: 225-238.
26. Xiong, Y., Q. F. Collins, J. An, E. Lupo, Jr ., H. Y. Liu, D. Liu, J. Robidoux, Z. Liu, and W. Cao. 2007. p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis. J. Biol. Chem. 282: 4975-4982.
27. Yang, J., M. L. MacDougall, M. T. McDowell, L. Xi, R. Wei, W. J. Zavadoski, M. P. Molloy, J. D. Baker, M. Kuhn, O. Cabrera, et al. 2011. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes. BMC Genomics. 12: 281.
28. Gu, W., H. Yan, K. A. Winters, R. Komorowski, S. Vonderfecht, L. Atangan, G. Sivits, D. Hill, J. Yang, V. Bi, et al. 2009. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J. Pharmacol. Exp. Ther. 331: 871-881.
29. Nigro, J., N. Osman, A. M. Dart, and P. J. Little. 2006. Insulin resistance and atherosclerosis. Endocr. Rev. 27: 242-259.